Insider Buying: Immunic, Inc. (NASDAQ:IMUX) CEO Buys 5,000 Shares of Stock

Immunic, Inc. (NASDAQ:IMUXGet Rating) CEO Daniel Vitt acquired 5,000 shares of the stock in a transaction on Friday, June 3rd. The shares were acquired at an average price of $3.10 per share, for a total transaction of $15,500.00. Following the acquisition, the chief executive officer now owns 368,877 shares of the company’s stock, valued at approximately $1,143,518.70. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Shares of NASDAQ:IMUX opened at $3.39 on Monday. The firm has a market capitalization of $103.53 million, a PE ratio of -1.08 and a beta of 2.00. Immunic, Inc. has a twelve month low of $2.52 and a twelve month high of $15.12. The company has a 50-day moving average price of $7.88 and a two-hundred day moving average price of $9.77.

IMUX has been the subject of several analyst reports. Piper Sandler lowered their target price on shares of Immunic from $71.00 to $39.00 and set an “overweight” rating for the company in a report on Tuesday, May 17th. Zacks Investment Research downgraded shares of Immunic from a “hold” rating to a “sell” rating in a report on Tuesday, May 3rd. StockNews.com started coverage on shares of Immunic in a report on Thursday, March 31st. They issued a “sell” rating for the company. SVB Leerink reduced their price target on shares of Immunic from $45.00 to $9.00 and set an “outperform” rating for the company in a research report on Friday. Finally, Wedbush reduced their price target on shares of Immunic from $61.00 to $14.00 in a research report on Thursday. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $20.00.

A number of large investors have recently modified their holdings of IMUX. JPMorgan Chase & Co. boosted its position in shares of Immunic by 9.4% in the fourth quarter. JPMorgan Chase & Co. now owns 11,262 shares of the company’s stock valued at $108,000 after acquiring an additional 965 shares during the period. Royal Bank of Canada raised its stake in shares of Immunic by 10.3% during the third quarter. Royal Bank of Canada now owns 13,350 shares of the company’s stock valued at $118,000 after acquiring an additional 1,242 shares during the last quarter. Citigroup Inc. raised its stake in shares of Immunic by 38.8% during the fourth quarter. Citigroup Inc. now owns 5,525 shares of the company’s stock valued at $53,000 after acquiring an additional 1,544 shares during the last quarter. American International Group Inc. raised its stake in shares of Immunic by 17.9% during the third quarter. American International Group Inc. now owns 10,245 shares of the company’s stock valued at $91,000 after acquiring an additional 1,554 shares during the last quarter. Finally, Deutsche Bank AG raised its stake in shares of Immunic by 16.9% during the third quarter. Deutsche Bank AG now owns 10,768 shares of the company’s stock valued at $95,000 after acquiring an additional 1,559 shares during the last quarter. Hedge funds and other institutional investors own 49.03% of the company’s stock.

Immunic Company Profile (Get Rating)

Immunic, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.

Further Reading

Insider Buying and Selling by Quarter for Immunic (NASDAQ:IMUX)

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.